At a glance
ClinicalIndex Comparison RecordN/ACompleted· 860 enrolled
Drug / intervention
Neurological assessmentbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
International Neurological Study: A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combination for Initial Treatment of HIV-1 Infected Individuals From Diverse Areas of the World)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·observational·Posted Nov 16, 2004·Updated Mar 18, 2015
In Brief
An observational study evaluating Neurological assessment for HIV Infections. Completed, enrolled 860 participants across 11 sites in 5 countries.
Detailed Summary
The purpose of this study is to determine how often dementia and other neurological problems occur in people with HIV. Participants of ACTG A5175 will enroll in this study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesBrazil, India, Malawi, South Africa, Zimbabwe
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2004
Enrollment StartFeb 2006
Primary CompletionMay 2010
TodayJul 2026
First PostedNov 16, 2004
Enrollment StartFeb 1, 2006
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 21.6 years ago
Interventions
Neurological assessmentbehavioral
All participants will undergo neurological examinations and neuropsychological assessments.